On February 3, 2022, TAG in collaboration with the International Network of People who Use Drugs (INPUD), Harm Reduction International (HRI), and the World Hepatitis Alliance (WHA), hosted this free webinar.
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
On November 4, 2021, Treatment Action Group and the International Treatment Preparedness Coalition presented this webinar outlining the main findings of the upcoming report "Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends."
This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.
Delivering on the Promise of Long-Acting Forumulations delves deep into the development of long-acting formulations for the treatment and prevention of infectious diseases like HIV, tuberculosis, hepatitis C, and malaria. Long-acting medications have become common for conditions such as osteoporosis and schizophrenia, and they're even used for birth control.
Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.
On September 11 2021, Treatment Action Group’s Joelle Dountio Ofinboudem presented new data on the registration of the hepatitis C cure at the Conference on Liver Disease in Africa (COLDA) 2021. The presentation titled, “Have a Heart, Save My Liver! Who Has Access to the Cure in Africa,” explains that accelerating treatment uptake across Africa is urgently needed to meet WHO hepatitis C targets by 2030.
TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.
Our resource compendium is a non-exhaustive list of materials covering long-acting technologies to inform the hepatitis C, latent tuberculosis infection, and malaria scope of work under the LONGEVITY Project. Long-Acting Technologies Trials Tracker Illustrated Glossary for Long-Acting Technologies Select Scientific…
The Illustrated Glossary for Long-Acting Technologies compiles frequent terms and concepts used in the research and development of long-acting technologies. The glossary is a non-exhaustive list and the graphics are artistic renderings meant to spur discussion and assist with community treatment literacy.